Home / Recalls / Teva North America / D-0005-2017

D-0005-2017 Class III Terminated

Recalled by Teva North America — Horsham, PA

FDA drug recall D-0005-2017 was initiated by Teva North America on August 5, 2016 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications. The recall status is terminated (terminated March 13, 2017). Affected quantity: 3,569 capsules.

Recall Details

Product Type
Drugs
Report Date
October 12, 2016
Initiation Date
August 5, 2016
Termination Date
March 13, 2017
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
3,569 capsules

Product Description

Claravis (isotretinoin capsules USP), 10mg, packaged in carton containing 3 Blister Packs of 10 Capsules Each (30 Capsules total); Rx only, TEVA PHARMACEUTICALS USA, Sellersville, PA 18960. NDC 00555-1054-86

Reason for Recall

Failed Impurities/Degradation Specifications.

Distribution Pattern

Nationwide

Code Information

Lot #: 34025714A, Exp. Date 12/2016

Other recalls by Teva North America

  • D-1453-2016 Class III — Children's Qnasl 40 mcg (beclomethasone dipropionate) Nasal Aerosol, 40 mcg per (July 15, 2016)
  • D-1470-2016 Class II — Amoxicillin for Oral Suspension USP, 400 mg/ 5 mL, 50 mL bottle, Rx only, Manufa (June 24, 2016)
  • D-1455-2016 Class II — Albuterol Sulfate Syrup, 2 mg/ 5 mL, 473 mL bottle, Rx only, Manufactured in Can (June 22, 2016)
  • D-1494-2016 Class II — ARGATROBAN Injection in 0.9% Sodium Chloride 250 mg/250 mL (1 mg/mL) , Rx Only, (June 17, 2016)
  • D-1495-2016 Class II — Linezolid Injection 600 mg/300 mL Rx Only, Manufactured in Hungary for TEVA PHAR (June 17, 2016)
  • D-1496-2016 Class II — Eptifibatide Injection 75 mg/100 mL (0.75 mg/mL) single use vial, For Intravenou (June 17, 2016)
  • D-1497-2016 Class II — Ondansetron Injection USP 40 mg/20 mL (2 mg/mL), Rx Only, Manufactured in Hungar (June 17, 2016)
  • D-1451-2016 Class III — mitoXANTRONE Injection USP (concentrate), 20 mg/10 mL (2 mg/mL), 10 mL Multiple (May 31, 2016)
  • D-1449-2016 Class III — Divalproex Sodium Delayed-release Tablets USP, RX, 250 mg, 100 count bottles, Ma (May 18, 2016)
  • D-0868-2016 Class II — Linezolid Injection, 600 mg/300 mL Single use container bags (NDC 0703-9060-31), (April 27, 2016)

FDA data resources